

# Randomized, optimal dose finding, Phase II Study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD)

Masato Takahashi<sup>1</sup>, Fumikata Hara<sup>2</sup>, Masahiro Kitada<sup>3</sup>, Yuichiro Kikawa<sup>4</sup>, Hiroaki Kato<sup>5</sup>, Eiko Sakata<sup>6</sup>, Yoichi Naito<sup>7</sup>, Yoshie Hasegawa<sup>8</sup>, Tsuyoshi Saito<sup>9</sup>, Tsutomu Iwasa<sup>10</sup>, Junji Tsurutani<sup>11</sup>, Naruto Taira<sup>12</sup>, Tsutomu Takashima<sup>13</sup>, Kosuke Kashiwabara<sup>14</sup>, Tomohiko Aihara<sup>15</sup>, Hirofumi Mukai<sup>7</sup>;

<sup>1</sup>NHO Hokkaido Cancer Center, Sapporo, Japan; <sup>2</sup>Cancer Institute Hospital of JFCR, Koto, Tokyo, Japan; <sup>3</sup>Asahikawa Medical University Hospital, Asahikawa, Japan; <sup>4</sup> Kobe City Medical Center General Hospital, Kobe, Japan an; <sup>5</sup>Teine Keijinkai Hospital, Sapporo, Japan; <sup>6</sup>Niigata City General Hospital, Niigata, Japan; <sup>7</sup> National Cancer Center Hospital East, Kashiwa, Japan; <sup>8</sup> Hirosaki Municipal Hospital, Hirosaki, Japan; <sup>9</sup>Japanese Red Cross Saitama Hospital, Saitama, Japan; <sup>10</sup> Kindai University Faculty of Medicine, Sayama, Japan ; <sup>11</sup> Advanced Cancer Translational Research Institute Showa University, Shinagawa, Japan; <sup>12</sup>Okayama University Hospital, Okayama, Japan; <sup>13</sup>Osaka City University Graduate School of Medicine, Osaka, Japan; <sup>14</sup> The University of Tokyo Hospital, Bunkyo, Japan ; <sup>15</sup>Aihara Hospital, Minoh, Japan

# Conflict of Interest disclosure slide for representative speakers or investigators



<b>Research fund</b>	<input type="checkbox"/> scientific research fund <input type="checkbox"/> contract <input type="checkbox"/> donation <input checked="" type="checkbox"/> other ( CSPOR-BC ) <input type="checkbox"/> N/A	<b>Sponsor</b>	Taiho co ltd.
----------------------	--	----------------	---------------

<b>Name of lead presenter</b>	Masato Takahashi	<b>Institution or company/position</b>	NHO Hokkaido Cancer Center / Deputy Director
-------------------------------	------------------	--	--

	No	If yes, please specify the name of company, organization, your status.
employee or adviser of company and/or profit-making organization	■	
profit of stock	■	
patent fee	■	
lecturer fee	<input type="checkbox"/>	Astra Zeneca, Eisai, Eli Lilly, pfizer
manuscript fee	■	
research expenses from company	■	
contributions or endowed chair	■	
fees of testimony, judgment, comment, etc.	■	
presents or other payment	■	
representative of organization for clinical study receiving research expenses from company	■	

<b>Name of principal investigator</b>	Fumikata Hara	<b>Institution or company/position</b>	Cancer Institute Hospital of JFCR / Chief, Breast Medical Oncology
---------------------------------------	---------------	--	--

	No	If yes, please specify the name of company, organization, your status.
employee or adviser of company and/or profit-making organization	■	
profit of stock	■	
patent fee	■	
lecturer fee	<input type="checkbox"/>	Kyowa-Kirin, pfizer
manuscript fee	■	
research expenses from company	■	
contributions or endowed chair	■	
fees of testimony, judgment, comment, etc.	■	
presents or other payment	■	
representative of organization for clinical study receiving research expenses from company	■	

# Background

---

- Although nab-paclitaxel (nab-PTX) has shown superior efficacy compared to conventional paclitaxel in metastatic breast cancer (MBC), chemotherapy induced peripheral neuropathy (CIPN) was more frequently observed in nab-PTX<sup>1</sup>.
- In a single arm Phase 2 trial (CA002-OLD), low dose nab-PTX (175mg/m<sup>2</sup>) every 3 weeks (q3w) demonstrated a good objective response rate (39.5%) without grade 3 or higher CIPN<sup>2</sup>.
- Herein, we conducted multicenter randomized controlled study to evaluate optimal dose of nab-PTX comparing lower dose (Low dose: LD or Medium dose: MD) to standard dose (SD).

# Study design

## Multicenter rP2 study

Patients with  
HER2-negative MBC  
in 1<sup>st</sup> or 2<sup>nd</sup> line  
Chemotherapy  
for MBC (N = 138)

### Stratification factors

- Hormone receptor
- DFI
- Institution
- Prior chemotherapy
- Prior taxane

R

**SD260 (standard dose) arm:**  
Nab-Paclitaxel: 260 mg/m<sup>2</sup>, q3w IV

**MD220 (Medium dose) arm**  
Nab-Paclitaxel: 220 mg/m<sup>2</sup>, q3w IV

**LD180 (Low dose) arm**  
Nab-Paclitaxel: 180 mg/m<sup>2</sup>, q3w IV

These treatments were repeated until PD or unacceptable toxicity

MBC: metastatic breast cancer, PD: progressive disease

DFI: Disease-free interval

# Study Objectives

---

- To evaluate non-inferiority of low dose nab-PTX compared to current standard dose 260mg/m<sup>2</sup> of nab-PTX in 1st or 2nd line chemotherapy for metastatic breast cancer.
- To compare adverse events including chemotherapy-induced peripheral neuropathy (CIPN), health-related QOL (HRQOL), and Patient Reported Outcomes (PROs) between the three different doses of nab-PTX.

# Endpoints

---

## ■ Primary endpoints

- Progression-free Survival (PFS)
- Incidence of Grade 3/4 chemotherapy induced peripheral neuropathy (CIPN)

## ■ Secondary endpoints

- Time to treatment failure (TTF)
- Overall survival (OS)
- Overall response rate (ORR)
- Disease control rate (DCR)
- Adverse events (AEs)
- Health-related quality of life (HR-QoL)
  - FACT-G, FACT-Taxane, EQ-5D, PNQ, CFS, BCSS
  - (Detailed results of HR-QoL will be planned to present at SABCS this year.)
- SNPs associated with CIPN (Translational research)

# Key patient eligibility criteria

---

- Female and aged between 20 and 75 years
- PS 0 or 1 (ECOG scale)
- Histologically confirmed breast cancer
- Metastatic/ advanced breast cancer
- Never received or 1 regimen of cytotoxic chemotherapy for MBC
- Adequate organ functions
- Peripheral neuropathy  $\leq$  grade 1


# Statistics

---

- Optimal dose was selected by 2 step selection. At first, if hazard ratio (HR) for PFS was less than 0.75 or more than 1.33, the inferior dose was dropped. Then, if estimated incidence rate of grade 3/4 neurotoxicity exceed 10% estimated by the logistic regression, that dose was also dropped.
- The study was planned to ensure to select MD220 with a probability of 70%, when the one-year PFSs of the three doses are all 30% and the grade 3 neurotoxicity rates of SD260, MD220 and LD180 are 15%, 8% and 0.1%, respectively, which requires 42 patients per group with expected registration period of two years and mean follow-up period of two years, and finally 46 patients per group was chosen.



# CONSORT diagram




FAS: Full analysis set

# Patients characteristics (FAS: Full analysis set)


	SD260 (n=47)	MD220 (n=45)	LD180 (n=48)	P-value
Median age, yrs (range)	59.0 (36–75)	61.0 (34–74)	58.5 (35–74)	0.82
PS (ECOG)				0.22
0	38 (80.9%)	34 (75.6%)	31 (64.6%)	
1	9 (19.1%)	10 (22.2%)	17 (35.4%)	
ER-positive	38 (80.9%)	34 (75.6%)	37 (77.1%)	0.88
PgR-positive	29 (61.7%)	22 (48.9%)	27 (56.3%)	0.53
Disease-free interval				0.93
De novo	13 (27.7%)	12 (26.7%)	11 (22.9%)	
≥ 2 years	27 (57.4%)	24 (53.3%)	27 (56.3%)	
< 2 years	7 (14.9%)	9 (20.0%)	10 (20.8%)	
Chemotherapy for MBC				0.96
Yes	12 (25.5%)	11 (24.4%)	13 (27.1%)	
No	35 (74.5%)	34 (75.6%)	35 (72.9%)	
Prior taxane therapy				0.88
Yes	19 (40.4%)	17 (37.8%)	17 (35.4%)	
No	28 (59.6%)	28 (62.2%)	31 (64.6%)	

# Progression-free Survival (FAS)




# Incidence of G3/4 neuropathy (FAS)

---



# Incidence of G2/3/4 neuropathy (FAS)

---



# Selection of optimal dose

## ■ First selection (equivalence)

Cox regression	Hazard ratio (HR)		Selection <sup>1)</sup>
	Estimate	95% CI	
MD220 vs SD260	0.73	(0.42, 1.28)	Drop SD260 due to HR<0.75
LD180 vs SD260	0.77	(0.47, 1.28)	Equivalent
LD180 vs MD220	0.96	(0.56, 1.66)	Equivalent

1) If HR <0.75 or >1.33, the inferior one will be dropped.

## ■ Second selection (peripheral sensory neuropathy)

Logistic regression	Incidence (%)		Selection <sup>2)</sup>
	Estimate	95% CI	
SD260	29.5	(18.7, 43.2)	Not candidate for 2 <sup>nd</sup> selection
MD220	14.0	(8.8, 21.6)	Drop MD220 due to estimated incidence rate exceeding 10%
LD180	5.9	(2.3, 14.6)	Retain LD180


2) The dose with its estimated incidence rate exceeding 10% will be dropped.

■ Finally selected dose **LD180**

# Second selection (Incidence of CIPN)

## Estimated incidence rate of grade 3/4 neurotoxicity by the logistic regression: cut off 10%

---



# Overall Response Rate (FAS)

---

	Treatment								
	SD260			MD220			LD180		
Measurable	n	%	95% CI	n	%	95% CI	n	%	95% CI
No. Pts	39			34			37		
Response	19	48.7	(32.4, 65.2)	15	44.1	(27.2, 62.1)	14	37.8	(22.5, 55.2)



# Dose reduction (FAS)

	Treatment Arm								
	SD260 (n=47)			MD220 (n=45)			LD180 (n=48)		
Dose reduction	n	%	95% CI	n	%	95% CI	n	%	95% CI
Yes	19	40.4	(26.4, 55.7)	11	24.4	(12.9, 39.5)	7	14.6	(6.1, 27.8)
No. of dose reduction									
1	14	29.8	(17.3, 44.9)	8	17.8	(8, 32.1)	6	12.5	(4.7, 25.2)
2	5	10.6	(3.5, 23.1)	3	6.7	(1.4, 18.3)	1	2.1	(0.1, 11.1)
By treatment course									
By 1 <sup>st</sup> course	0	0.0	(0, 7.5)	0	0.0	(0, 7.9)	0	0.0	(0, 7.4)
By 2 <sup>nd</sup> course	3	6.4	(1.3, 17.5)	1	2.2	(0.1, 11.8)	0	0.0	(0, 7.4)
By 3 <sup>rd</sup> course	4	8.5	(2.4, 20.4)	2	4.4	(0.5, 15.1)	0	0.0	(0, 7.4)

# Adverse Events (FAS)

Events	SD260: n, (%)		MD220: n, (%)		LD180: n, (%)	
	Any	Grade≥3	Any	Grade≥3	Any	Grade≥3
No. of pts	n =47		n =45		n =48	
Leukopenia	31 (66.0)	9 (19.1)	35 (77.8)	12 (26.6)	29 (60.4)	7 (14.6)
Neutropenia	27 (57.4)	12 (25.4)	33 (73.3)	17 (37.7)	24 (50.0)	7 (14.6)
Hemoglobin	27 (57.4)	1 (2.1)	22 (48.9)	1 (2.2)	28 (58.3)	2 (4.2)
ALT elevation	26 (55.3)	1 (2.1)	20 (44.4)	2 (4.4)	18 (37.5)	0 (0.0)
Fatigue	38 (80.9)	1 (2.1)	35 (77.8)	0 (0.0)	34 (70.8)	0 (0.0)
Sensory neuropathy	43 (91.5)	15 (31.9)	38 (84.4)	4 (8.9)	39 (81.3)	4 (8.3)
Arthralgia	35 (74.5)	4 (8.5)	30 (66.7)	5 (11.1)	27 (56.3)	0 (0.0)
Myalgia	34 (72.3)	6 (12.8)	26 (57.8)	3 (6.7)	19 (39.6)	0 (0.0)
Rash	16 (34.1)	0 (0.0)	14 (31.1)	0 (0.0)	12 (25.0)	0 (0.0)
Anorexia	24 (51.1)	1 (2.1)	23 (51.1)	0 (0.0)	20 (41.7)	1 (2.1)

## Conclusions

---

- Low dose nab-PTX at 180 mg/m<sup>2</sup>/3 weeks could be an optimal dose with good clinical efficacy and tolerability for patients with MBC.

# Acknowledgement

---

To all of the patients who participated in ABROAD and their families

To the investigators and research coordinators at the 41 institutions and CSPOR-BC.

The research fund was provided to CSPOR-BC by Taiho Pharmaceutical Co., Ltd under the study contract. All decisions concerning the planning, implementation and publication of this study were made by the executive committee of this study.